Shift Bioscience Information

Operating at the intersection of machine learning and cell biology, Shift’s target discovery platform leverages large-scale proprietary datasets and virtual cell models to link cellular aging to disease states. The Company is progressing a pipeline of cell rejuvenation targets, identifying an initial siRNA program in liver fibrosis (MASH and non-MASH) with unique expansion potential to the most advanced and age-driven forms of fibrosis. Cambridge (UK) based with a team spanning Longevity, virtual cells, siRNA and liver disease, Shift is open to strategic partnerships that accelerate the first medicines capable of prolonging both healthspan and lifespan.